docetaxel anhydrous has been researched along with pyrazines in 27 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (pyrazines) | Trials (pyrazines) | Recent Studies (post-2010) (pyrazines) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 12,165 | 1,373 | 5,747 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.41) | 18.2507 |
| 2000's | 21 (77.78) | 29.6817 |
| 2010's | 4 (14.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braguer, D; Briand, C; Carles, G; Garcia, P | 2 |
| von Mehren, M | 1 |
| McConkey, DJ; Nawrocki, ST; Sweeney-Gotsch, B; Takamori, R | 1 |
| Reddy, KG | 1 |
| Dreicer, R; Price, N | 1 |
| Kaplow, R | 1 |
| Alexandre, J | 1 |
| Almuete, VI; Armstrong, DK; Baker, SD; Carducci, MA; Dinh, K; Donehower, RC; Lassiter, L; Messersmith, WA; Sullivan, RA; Wright, JJ | 1 |
| Soria, JC | 1 |
| Canfield, SE; McConkey, DJ; Williams, SA; Zhu, K | 1 |
| Akerley, W; Axelrod, R; Belt, R; Carbone, DP; Crawford, J; Fanucchi, MP; Fidias, P; Fossella, FV; Govindan, R; Kashala, O; Kelly, K; Limentani, SA; Natale, R; Raez, LE; Reimers, HJ; Ribeiro, M; Robert, F; Schiller, JH; Sheng, S | 1 |
| Fenk, R; Garcia-Pardillos, G; Haas, R; Kronenwett, R; Meier, A; Neukirchen, J; Rohr, UP; Rohrbeck, A; Steidl, U | 1 |
| Agus, D; Dreicer, R; Petrylak, D; Roth, B; Webb, I | 1 |
| Jung, CS; Khuri, FR; Sun, SY; Zhou, Z | 1 |
| Davies, AM; Doroshow, JH; Gandara, DR; Gumerlock, PH; Kashala, O; Koczywas, M; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Quinn, DI; Schenkein, D | 1 |
| Barton, J; Gould, B; Greco, FA; Hainsworth, JD; Meluch, AA; Meng, C; Simons, L; Spigel, DR | 1 |
| Ackermann, H; Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Strebhardt, K; Wagenblast, J | 1 |
| Banu, E; Beuzeboc, P; Guyader, C; Medioni, J; Oudard, S; Scotte, F | 1 |
| Bae, SH; Hyun, MS; Kim, MK; Lee, KH; Ryoo, HM; Sin, JI | 1 |
| Albanell, J; Awada, A; Baselga, J; Canney, PA; Cardoso, F; Dirix, LY; Gascon, P; Gil, T; Piccart, MJ | 1 |
| Cao, W; Namiki, K; Porvasnik, S; Rosser, CJ; Sakai, Y; Shiverick, KT; Urbanek, C | 1 |
| Gu, L; Kirshner, J; Lerro, K; Lilenbaum, R; Vokes, E; Wang, X | 1 |
| Aulino, J; Baumann, J; Burkey, B; Chung, CH; Cmelak, AJ; Gilbert, J; Hatakeyama, H; Muldowney, NJ; Murphy, BA; Netterville, J; Parker, J; Shyr, Y; Sinard, R; Slebos, RJ; Yarbrough, WG | 1 |
| Fujisawa, M; Miyake, H; Sakai, I; Terakawa, T | 1 |
| Argiris, A; Belani, CP; Gandara, DR; Gitlitz, B; Koczywas, M; Lara, PN; Lau, DH; Leighl, N; Longmate, J; Mack, PC; Ramalingam, S; Reckamp, K; Shepherd, FA; Wright, JJ | 1 |
| Butler, LM; Castillo, L; Centenera, MM; Daly, RJ; Grogan, J; Haynes, AM; Horvath, LG; Kench, JG; Lee, BY; Lin, HM; Shreeve, SM; Spielman, C; Stricker, PD; Yeung, NK | 1 |
3 review(s) available for docetaxel anhydrous and pyrazines
| Article | Year |
|---|---|
New therapeutic strategies for soft tissue sarcomas.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Docetaxel; Epothilones; Guanidines; Humans; Indoles; Isoquinolines; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Pyrroles; Sarcoma; Sirolimus; Sunitinib; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2003 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
[New targeted therapies in hormone-refractory prostate cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Calcitriol; Cancer Vaccines; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Endothelin-1; Epothilones; Humans; Male; Oligonucleotides, Antisense; Organoplatinum Compounds; Prostatic Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Taxoids | 2007 |
10 trial(s) available for docetaxel anhydrous and pyrazines
| Article | Year |
|---|---|
Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids | 2004 |
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Taxoids; Treatment Outcome | 2006 |
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Taxoids; Treatment Outcome; United States | 2006 |
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Dose-Response Relationship, Drug; Humans; Interleukin-6; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Taxoids | 2007 |
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids; Treatment Outcome | 2007 |
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Topics: Adult; Aged; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Boronic Acids; Bortezomib; Breast Neoplasms; Breast Neoplasms, Male; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Pyrazines; Spain; Taxoids; Treatment Outcome; United Kingdom; Vomiting | 2008 |
Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Docetaxel; Female; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2009 |
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Pyrazines; Recurrence; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pyrazines; Taxoids | 2011 |
14 other study(ies) available for docetaxel anhydrous and pyrazines
| Article | Year |
|---|---|
Simultaneous combination of microtubule depolymerizing and stabilizing agents acts at low doses.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cell Division; Colchicine; Demecolcine; Docetaxel; Humans; KB Cells; Microscopy, Fluorescence; Microscopy, Immunoelectron; Microtubule Proteins; Microtubules; Paclitaxel; Pyrazines; Pyridines; Taxoids; Tubulin | 1995 |
[Effect of the association of antimitotic agents on cell lines of human adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carbamates; Colonic Neoplasms; Docetaxel; Humans; Paclitaxel; Pyrazines; Pyridines; Skin Neoplasms; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 1994 |
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protease Inhibitors; Pyrazines; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Prognosis; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Randomized Controlled Trials as Topic; Research; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A | 2006 |
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Humans; Male; Prostatic Neoplasms; Pyrazines; Taxoids; Tumor Cells, Cultured | 2006 |
The proteasome inhibitor bortezomib acts differently in combination with p53 gene transfer or cytotoxic chemotherapy on NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Genes, p53; Genetic Therapy; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Transfection; Tumor Cells, Cultured | 2007 |
Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Docetaxel; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Survivin; Taxoids; Tumor Cells, Cultured | 2007 |
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines; Taxoids | 2008 |
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Humans; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms; Taxoids; Tumor Suppressor Protein p53 | 2008 |
Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Down-Regulation; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured | 2008 |
Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Taxoids; Tumor Cells, Cultured | 2011 |
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Humans; Immunoblotting; Immunohistochemistry; Male; Mice; Prostate; Prostatic Neoplasms, Castration-Resistant; Pyrazines; Sulfonamides; Xenograft Model Antitumor Assays | 2018 |